Immix Biopharma Investor Presentation Deck
N-GENIUS Platform: EXPAND Technology + COBRA Binder (2/2)
All BCMA CAR-Ts Are Not Created Equal
CD3Zy
4-1BB
Overview Of Custom EXPAND Technology + COBRA Binder in NXC-201
CD8
Transmembrane
Protein
1 Proprietary Optimized CD3Z- 2
"CD3Zy"
N-GENIUS PLATFORM
NXC-201
EXPAND Technology + COBRA Binder
CD8
Hinge
Source:. Aherie, N., et al Haematologica. 2022; LaFleur, D. PEGS Boston. 2021
Tumor Binding Domain
Proprietary Optimized CD8
Hinge Flexibility
Delivers "Digital" Intracellular Signaling
Eliminates Neurotoxicity, Reduce CRS Duration
Enhances Efficacy In Heavily Pretreated Patients
CD8
Signaling
Protein
"Single amino acid substitutions at key sites can affect CAR-T function over 200-fold range"
3
●●●
IMMİX
S BIOPHARMA
EXPAND Technology + COBRA Binder
Modifications
Proprietary Optimized
COBRA Binder Enhances
Tumor Binding + Ensures
High Expression
10View entire presentation